Iara Rossi1, Sabrina Royer2, Melina Lorraine Ferreira2, Paola Amaral Campos2, Bruna Fuga2, Gabriel Nogueira Melo2, Luiz Gustavo Machado2, Daiane Silva Resende2, Deivid Batistão3, Jane Eire Urzedo4, Paulo P Gontijo-Filho2, Rosineide Marques Ribas5. 1. Laboratory of Molecular Microbiology, Biomedical Science Institute, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil. Electronic address: iararossi@ufu.br. 2. Laboratory of Molecular Microbiology, Biomedical Science Institute, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil. 3. Laboratory of Molecular Microbiology, Biomedical Science Institute, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil; School of Medicine, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil. 4. Hospital Infection Control Committee, Hospital das Clínicas, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil. 5. Laboratory of Molecular Microbiology, Biomedical Science Institute, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil; Hospital Infection Control Committee, Hospital das Clínicas, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil.
Abstract
BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CR-Ab) has become a worrying health care problem, mainly in developing countries, such as Brazil. The objective was to investigate the prevalence and prognostic factors for CR-Ab infections at a Brazilian university hospital and examine the impact of inappropriate antimicrobial therapy on patient outcome. METHODS: A retrospective study on hospitalized patients with CR-Ab infections was carried out from January 2013 to December 2017. An epidemiologic analysis was carried out to determine the frequency of infections, the epidemiologic indicators by year, the risk factors for 30-day mortality, and the impact of inappropriate therapy. RESULTS: A total of 489 patients were included in the study. A rate of 0.7 per 1,000 patient-day CR-Ab infections was observed, mostly in the lungs (54.7%), and predominantly in the adult intensive care unit. The occurrence of infections by CR-Ab per 1,000 patient-days in November 2014 exceeded the established control limit, confirming an outbreak. CONCLUSIONS: The prevalence of CR-Ab increased in the investigated hospital, passing to an endemic pathogen with a direct impact on mortality and the control of these strains.
BACKGROUND:Carbapenem-resistant Acinetobacter baumannii (CR-Ab) has become a worrying health care problem, mainly in developing countries, such as Brazil. The objective was to investigate the prevalence and prognostic factors for CR-Ab infections at a Brazilian university hospital and examine the impact of inappropriate antimicrobial therapy on patient outcome. METHODS: A retrospective study on hospitalized patients with CR-Ab infections was carried out from January 2013 to December 2017. An epidemiologic analysis was carried out to determine the frequency of infections, the epidemiologic indicators by year, the risk factors for 30-day mortality, and the impact of inappropriate therapy. RESULTS: A total of 489 patients were included in the study. A rate of 0.7 per 1,000 patient-day CR-Ab infections was observed, mostly in the lungs (54.7%), and predominantly in the adult intensive care unit. The occurrence of infections by CR-Ab per 1,000 patient-days in November 2014 exceeded the established control limit, confirming an outbreak. CONCLUSIONS: The prevalence of CR-Ab increased in the investigated hospital, passing to an endemic pathogen with a direct impact on mortality and the control of these strains.
Authors: Thomas M Elliott; Patrick N Harris; Leah W Roberts; Michelle Doidge; Trish Hurst; Krispin Hajkowicz; Brian Forde; David L Paterson; Louisa G Gordon Journal: Antimicrob Steward Healthc Epidemiol Date: 2021-12-13